title: [Experience in complex therapy ribavine chronic viral hepatitis C].
abstract: In 72 patients with chronic hepatitis C aged 18 to 62 years evaluated the clinical efficacy Ribavine in combination therapy with interferon-alpha. The safety, good tolerability and efficacy Ribavine. Persistent virological and biochemical response in the application of interferon-alpha and Ribavine obtained from 47,5 to 53,1%. Recurrence rate was 32,5% in patients with genotype 1 and 21,9% with genotype 2 and 3. Side effects of Ribavine are reversible and leveled after the completion of therapy.
authors.forename: O M
authors.initials: OM
authors.lastname: Domashenko
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D004359:Drug Therapy, Combination / Q000379:methods*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects* / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D058889:Molecular Typing; D012367:RNA, Viral / Q000037:antagonists & inhibitors; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin